PTC/SB/08a (08-03)
Approved for use through 07/31/2006 ONS 0651-0201
U.S. Patient and Trademask Office; U.S. DEPARTMENT OF COMMERCE
d to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to resp

	Application Number			
INFORMATION DIGGS COURT	Filing Date			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Kazu		utomi OKA & Fumiaki IKUTA	
(Not for submission under 37 CFR 1.99)	Art Unit			
(Examiner Name			
	Attorney Docket Numb	er	1-245	

U.S.PATENTS									Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	Date Name of Patentee or Applicant			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1										
If you wish	h to a	dd additional U.S. Pater							Add		
U.S.PATENT APPLICATION PUBLICATIONS Remove											
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Pate of cited Docu	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1										
If you wish to add additional U.S. Published Application citation information please click the Add button. Add											
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4	Publication Date	ation Name of Patentee or Applicant of cited Document		where Rel	or Relevant	Τs
	1	2000-326036	JP			2000-11-28					
	2	8-1271	JP			1996-01-09					
	3	49799906	JP			1974-08-01					

Application Number Filing Date STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Art Unit Examiner Name Attorney Docket Number | 1-245

1980-03-05

	5	2000-17325	JP		2000-01-18				
	6	53-99014	JP		1978-08-30				
	7	60-186939	JP		1985-12-11				
If you wis	h to a	dd additional Foreign P	atent Document	citation	information pl	ease click the Add butto	n Add		
	NON-PATENT LITERATURE DOCUMENTS Remove								
Examiner Initials*	Examiner Cite (notice name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and office country where published.								T5
	1								
If you wish to add additional non-patent literature document citation information please click the Add button Add									

¹ See Kind Codes of USPTO Patient Documents at www.<u>USPTO.GDV</u> or MPEP 901.04. ² Enter office that resued the document, by the two-letter code (WIPO Standard 513.) ³ Fee Impacts patient forcers patient documents, the includion of the year of the region of the Engineer must preced the serial number of the patient documents. The patient documents will be a patient document of the patient standard to the patient document of the patient of the patient document to the patient of bearing at 15 feet above. ⁴ Applicated to a feature to a feature of the patient document under the Document to a feature the patient document to the patient of the patient documents. ⁴ Applicated to the patient document to the patient do

EXAMINER SIGNATURE

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Considered

Examiner Signature

4 55-31211

Application Number Filing Date Filing Date

CERTIFICATION STATEMENT

Ficase see 3/	CFR 1.57 all	a 1.50 to make	tile appropriate s	refection(s).	

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 197(e)(1)

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement was the filing of the information disclosure statement.

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

ionii oi tre signature.			
Signature	/james h walters/	Date (YYYY-MM-DD)	2006-08-18
Name/Print	James H. Walters	Registration Number	35731

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S. 2213.1-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313.1-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to a patient application or patient. If you do not furnish the requested the process another examine your submission, which may visually intermediate or of redesting to a submission or the basic log process another examine; your submission, which may visually intermediate or of redesting to a submission or the submission or the submission of the submission or the submission of the submission of the submission or the submission of the submission or the submission of the submission or the submission or the submission of the submission or the submission or the submission or the

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.